Pharmacology

Innovent Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Progress

Retrieved on: 
Monday, March 30, 2020

We are confident that Innovent is well positioned to sustain its rapid growth and deliver tremendous value for our patients and shareholders."

Key Points: 
  • We are confident that Innovent is well positioned to sustain its rapid growth and deliver tremendous value for our patients and shareholders."
  • Presented key results from 6 clinical studies of Tyvyt either orally or by posters/abstracts at ASCO in 2019.
  • Innovent will host a live conference call at 9:00 a.m. March 31, 2020 Beijing time to review its financial results and provide a general corporate progress.
  • Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts.

Detailed Insights on COVID-19 (Novel Coronavirus 19) - Identify Companies That Are Developing Therapies, Vaccines and Diagnostic Kits

Retrieved on: 
Monday, March 30, 2020

Government agencies, Institutions, Biotech companies, pharmaceutical companies, around the world are working exhaustively and actively in finding a cure and are focused on developing vaccines/drugs to prevent or treat COVID-19infection.

Key Points: 
  • Government agencies, Institutions, Biotech companies, pharmaceutical companies, around the world are working exhaustively and actively in finding a cure and are focused on developing vaccines/drugs to prevent or treat COVID-19infection.
  • The recently launched report covers a detailed analysis of 50+ companies working for the development of drugs and vaccines as well as diagnostics companies are working on developing test kits.
  • Few other companies are learning from earlier vaccines from prior coronavirus outbreaks and making them more effective.
  • How many companies are developing therapies, vaccines and diagnostic kits for the treatment of COVID- 19?

SpendEdge Unveils the Best Ways to Identify Suppliers in the Global Active Pharmaceutical Ingredients Market That Can Help Minimize the Impact of COVID-19 Outbreak

Retrieved on: 
Monday, March 30, 2020

SpendEdge, a leading provider of procurement market intelligence solutions, has announced the completion of their latest article on the ways to identify suppliers in the global active pharmaceutical ingredients market.

Key Points: 
  • SpendEdge, a leading provider of procurement market intelligence solutions, has announced the completion of their latest article on the ways to identify suppliers in the global active pharmaceutical ingredients market.
  • A huge number of manufacturers of active pharmaceutical ingredients that were responsible for the production of vital drugs are located within Chinese provinces.
  • At SpendEdge, we understand that companies use different approaches to develop active pharmaceutical ingredients.
  • COVID-19 outbreak has compelled pharmaceutical companies to collaborate with CMOs that extensively focus on developing innovative active pharmaceutical ingredients.

Companion Diagnostics Development Services Industry, 2020-2030 - Gradually Shifting from the Traditional, One-Drug-For-All Paradigm to Using Tailored Pharmacological Interventions - ResearchAndMarkets.com

Retrieved on: 
Monday, March 30, 2020

However, therapies tailored to specific disease-related molecular signatures require appropriate companion diagnostics in order to make physicians aware of patients' unique genetic profiles, enabling them to make informed treatment related decisions.

Key Points: 
  • However, therapies tailored to specific disease-related molecular signatures require appropriate companion diagnostics in order to make physicians aware of patients' unique genetic profiles, enabling them to make informed treatment related decisions.
  • In addition, it is worth noting that companion diagnostics guided drug development efforts have demonstrated to effectively reduce clinical trial costs by almost 60%.
  • Given the aforementioned advantages, the industry is gradually shifting from the traditional, one-drug-for-all, paradigm to using tailored pharmacological interventions.
  • In fact, nearly 80% of the companies are known to rely on external diagnostics developers for companion diagnostics development, mostly owing to the lack of in-house expertise.

Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, March 30, 2020

NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the year ended December 31, 2019.

Key Points: 
  • NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the year ended December 31, 2019.
  • 2019 and Recent Corporate Highlights:
    The stock purchase stage of the strategic transaction between InvaGen and Avenue closed in February 2019.
  • Also in October 2019, IV tramadol Phase 1 clinical data were published in the peer-reviewed journal Clinical Pharmacology in Drug Development.
  • Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value.

2020 Anal Cancer Pipeline Guide with Analysis by Indication, Stage of Development, Mechanism of Action, Route of Administration and Molecule Type

Retrieved on: 
Friday, March 27, 2020

This pipeline guide Global Anal Cancer Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • This pipeline guide Global Anal Cancer Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

RAMM Pharma Corp. Receives Federal Approval and Registration of XALEX™ 10 (cannabidiol) Oral Solution

Retrieved on: 
Thursday, March 26, 2020

The approval of XALEX 10 is a significant accomplishment for RAMM Pharma, offering patients another federally approved pharmaceutical CBD medicine, stated Jack Burnett, Chief Executive Officer.

Key Points: 
  • The approval of XALEX 10 is a significant accomplishment for RAMM Pharma, offering patients another federally approved pharmaceutical CBD medicine, stated Jack Burnett, Chief Executive Officer.
  • XALEX 10 is a 10% plant-derived pharmaceutical formulation of pure CBD approved by the MSP as an anti-epileptic medication for the treatment of seizures associated with refractory epilepsy.
  • The rigorous MSP approval process includes stability testing standards which conform to international pharmaceutical requirements for registered pharmaceutical products.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA and Ramm Pharma Holdings Corp.

Demand for Pharmaceutical Packaging to Double Through 2029; High Preference for Sustainable Packaging to Drive Market Growth, Says a New Fact.MR study

Retrieved on: 
Thursday, March 26, 2020

Fact.MR projects the growth rate of pharmaceutical packaging market at approximately 8% over the forecast period.

Key Points: 
  • Fact.MR projects the growth rate of pharmaceutical packaging market at approximately 8% over the forecast period.
  • Rising economic wealth, consumer sentience and global population are propelling the growth of pharmaceutical packaging market.
  • The millennial population in emerging economies in particular are projected to boost the demand for pharmaceutical packaging through 2029, reports Fact.MR in a new study.
  • Growing geriatric population in developed countries is a major growth contributor of pharmaceutical packaging market.

Joy Organics Launches Cooling CBD Sports Cream

Retrieved on: 
Thursday, March 26, 2020

FORT COLLINS, Colo., March 26, 2020 /PRNewswire/ --Joy Organics announced today the launch of its new, menthol-rich CBD Sports Cream.

Key Points: 
  • FORT COLLINS, Colo., March 26, 2020 /PRNewswire/ --Joy Organics announced today the launch of its new, menthol-rich CBD Sports Cream.
  • The wellness brand seeks to maximize muscle support by combining its premium broad-spectrum CBD with organic essential oils and camphor.
  • "Like most of our products, the new CBD Sports Cream came from asking our customers what they care about," said Joy Organics co-founder and CEO Joy Smith.
  • Joy Organics is a family-founded CBD business committed to leading the industry in quality and transparency.

Medigene Provides Results for Fiscal Year 2019 and Outlook

Retrieved on: 
Thursday, March 26, 2020

Medigene completed the Phase I/II clinical trial of the DC vaccine in AML patients in December 2019 and reported positive final 2-year topline results in January 2020.

Key Points: 
  • Medigene completed the Phase I/II clinical trial of the DC vaccine in AML patients in December 2019 and reported positive final 2-year topline results in January 2020.
  • These results were consistent with the 12-month interim analysis presented in 2019.
  • Medigene received an upfront payment of US $10 m and is eligible to receive potential development, regulatory, and commercial milestone payments.
  • Prof. Dolores Schendel, CEO/CSO at Medigene AG: In the past fiscal year we set the course for the expansion of our clinical programs.